The Good Governance for Medicines approach is to support policy-makers and national officials to understand where the strengths and weaknesses lie in the national pharmaceutical systems in order to develop and apply appropriate interventions. The programme has now been implemented in 36 countries worldwide.
The need for good governance in the pharmaceutical sector
Increasing access to medicines remains one of the major global challenges to achieve Universal health Coverage. In recent years governance has been identified as being crucial for universal access and sector performance, for example through increasing efficiency and reducing wastage. Good governance has been identified as a priority area of work in the WHO Medicines Strategy 2008-2013.
Medicines Transparency Alliance
Good governance and the critical need for evidence on effective interventions to increase access to medicines has been identified as a priority area of work by the WHO Medicines Strategy 2008-2013. Efforts of the Department for Essential Medicines and Health Products to improve good governance in the pharmaceutical sector, through policy and regulatory support initiatives and programmes such as the Medicines Transparency Alliance and Good Governance for Medicines, have generated considerable insight into understanding how good governance can impact on the availability and affordability of quality medicines.
WHO collaborates with many different stakeholders to improve governance in the pharmaceutical sector.
Medicines Transparency Alliance Global Meeting, Switzerland, December 2014
Representatives from participating countries from the public and private sectors, civil society and WHO shared experiences in improving access to quality essential medicines through improved transparency in the pharmaceutical sector.
GGM technical working group meeting, Tunis, March 2014
The GGM technical working group met in Tunis in March 2014 to discuss the development of guidance documents for the GGM programme. The report summarizes the discussions and recommendations of the participants.
Dr. Gilles Forte
Policy, Access and Use
Department of Essential Medicines and Health Products